Lupin launches Betamethasone Dipropionate Ointment USP (Augmented)
Pharma major Lupin Limited (Lupin) announced the launch of Betamethasone Dipropionate Ointment USP (Augmented), 0.05%, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin’s Pithampur (Unit III) facility, India
Manufacturing | 21/03/2020 | By Darshana | 1104
BELLUS Health Inc, a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders, today announced that it has completed patient enrollment for the RELIEF trial, its dose-escalation, placebo-controlled Phase 2 trial of BLU-5937 in patients
Manufacturing | 21/03/2020 | By Darshana | 707
Medivir and Tango Therapeutics sign license agreement for preclinical asset
Medivir today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one of Medivir’s preclinical research programs
Manufacturing | 17/03/2020 | By Darshana | 286
Lupin launches Ethacrynic Acid Tablets USP
Pharma major Lupin Limited (Lupin) announced the launch of Ethacrynic Acid Tablets USP, 25 mg, having received approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product would be manufactured at Lupin's Nagpur OSD facility, India
Manufacturing | 14/03/2020 | By Darshana | 892
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy